Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV 89557, USA.
Invest Ophthalmol Vis Sci. 2010 May;51(5):2479-86. doi: 10.1167/iovs.09-4414. Epub 2009 Dec 10.
Insulin-like growth factor 1 (IGF1) and cardiotrophin 1 (CT1) are known to increase the strength of extraocular muscles in adult and embryonic animals, but no information is available for the early postnatal period, when strabismus treatment in humans is most urgent. Here the authors sought to determine whether these trophic factors strengthen juvenile maturing extraocular muscles and gain insight into mechanisms of force increase.
After two injections of IGF1, CT1, or both with different dosages in posthatch chickens, the authors quantified five parameters of the superior oblique extraocular muscle at 2 weeks of age: contractile force, muscle mass, total myofiber area, myofiber diameter, and number of proliferating satellite cells labeled by bromodeoxyuridine.
Treatment with IGF1, CT1, and combination of IGF1 and CT1 significantly increased contractile force by 14% to 22%. CT1 and combination treatment significantly increased muscle mass by 10% to 24%. IGF1/CT1 combination treatment did not have additive effects on strengthening muscles, compared with single-drug treatments. Myofiber area increased significantly with IGF1 and CT1 treatment in proximal, but not distal, parts of the muscle and this was due to increased fiber numbers or length (IGF1) or increased diameters of global layer myofibers (CT1). Trophic factors increased the number of proliferating (bromodeoxyuridine-labeled) satellite cells in proximal and middle segments of muscles.
Exogenous IGF1 and CT1 strengthen extraocular muscles during maturation. They predominantly remodel the proximal segment of juvenile extraocular muscles. This information about muscle plasticity may aid the design of pharmacologic treatment of strabismus in children during the "critical period" of oculomotor maturation.
胰岛素样生长因子 1(IGF1)和心营养素 1(CT1)已知可增强成年和胚胎动物的眼外肌力量,但对于人类斜视治疗最为紧迫的早期产后阶段,尚无相关信息。作者在此试图确定这些营养因子是否可增强正在发育成熟的幼年眼外肌,并深入了解力量增加的机制。
在孵化后鸡的两次注射中,作者用不同剂量的 IGF1、CT1 或两者组合处理后,在 2 周龄时量化了上斜肌的 5 个参数:收缩力、肌肉质量、总肌纤维面积、肌纤维直径和标记有溴脱氧尿苷的增殖卫星细胞数量。
IGF1、CT1 和 IGF1/CT1 联合治疗可使收缩力显著增加 14%至 22%。CT1 和联合治疗可使肌肉质量显著增加 10%至 24%。与单一药物治疗相比,IGF1/CT1 联合治疗对增强肌肉没有相加作用。IGF1 和 CT1 治疗可使近端而非远端肌的肌纤维面积显著增加,这是由于纤维数量或长度增加(IGF1)或整个肌纤维层的直径增加(CT1)。营养因子增加了近端和中段肌肉中增殖(溴脱氧尿苷标记)卫星细胞的数量。
外源性 IGF1 和 CT1 在成熟过程中可增强眼外肌。它们主要重塑幼年眼外肌的近端节段。这些关于肌肉可塑性的信息可能有助于设计儿童斜视的药物治疗方案,以应对眼球运动成熟的“关键期”。